期刊文献+

体外膜肺氧合中抗凝管理研究进展

Research progress of anticoagulation management in ECMO
原文传递
导出
摘要 体外膜肺氧合(extracorporeal membrane oxygenation,ECMO)是重要的体外生命支持技术,可部分或完全替代患者心肺功能,对提高危重患者生存率中具有良好的临床应用价值。血栓形成和(或)出血事件是ECMO最常见的并发症,也是导致患者死亡的主要原因。抗凝管理与ECMO凝血或出血相关并发症之间有着直接的关系,但目前尚无标准的抗凝监测管理方式,各ECMO中心所采用的抗凝策略也不尽一致,笔者通过综述ECMO抗凝管理进展,为提高临床ECMO应用效果提供参考。
作者 戴吉 尹霄 汤铭阁 单祎 叶寅杰 董妮珊 郑鹏 陆俊杰 Ji Dai;Xiao Yin;Mingge Tang
出处 《中华卫生应急电子杂志》 2022年第5期304-308,共5页 Chinese Journal of Hygiene Rescue(Electronic Edition)
  • 相关文献

参考文献9

二级参考文献48

  • 1徐进,赵建,邵志华,孙晓红,柳月珍,张宪成,黄春倩,林娟,丁日高.兔全氟异丁烯中毒后血液学参数的变化[J].军事医学科学院院刊,2007,31(3):256-258. 被引量:2
  • 2Yang J, Ma YQ, Page RC et al. Structure of an integrin alphalIb beta3 transmembrane cytoplasmic heterocomplex provides insight into integrin activation [J]. Proc Natl Acad Sci U S A, 2009, 106 (42) : 17729-17734.
  • 3Hagemeyer CE, Peter K. Targeting the platelet integrin GPIlb/ IIIa [J]. Curr Pharm Des, 2010, 16 (37): 4119-4133.
  • 4Bledzka K, Smyth SS, Plow EF. lntegrin MIbβ3: from discovery to efficacious therapeutic target [J]. Circ Res, 2013, 112 (8): 1189-1200.
  • 5Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/Illa inhibi- tors in acute coronary syndromes: the ACUITY Timing trial [J]. JAMA, 2007, 297 (6): 591-602.
  • 6Kastrati A, Mehilli J, Neumann FJ, etah Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: tbe ISAR-REACT 2 randomized trial [J]. JAMA, 2006, 295 (13): 1531-1538.
  • 7Wang TY, White JA, Tricoci P, et al. Upstream elopidogrel use and the efficacy and safety of early eptifibatide treatment in pa tients with acute coronary syndrome: an analysis from the Early Glycoprotein Ilb/IIIa Inhibition in Palients with Non ST Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial [J]. Circulation, 2011, 123 (7): 722-730.
  • 8Pride YB, Mohanavelu S, Zorkun C, et al. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa lnhi bition in Non ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy [J]. JACC Cardiovasc Interv, 2012, 5 (9): 927 -935.
  • 9Tricoei P, Newby LK, Hasselblad V, et al. Upstream use of small molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systemat ic overview of randomized clinical trials [J]. Circ Cardiovasc Qual Outcomes, 2011, 4 (4): 448-458.
  • 10Valgimigli M, Campo G, de Cesare N, et al. Intensifying plate let inhibition with tirofiban in poor responders to aspirin, clopi dogrel, or both agents undergoing elective coronary intervention: results from the double blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to As- pirin and/or Resistance to Clopidogrei study [J]. Circulation, 2009, 119 (25): 3215-3222.

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部